公开(公告)号：DK0734249T3

公开(公告)日：1999-12-06

申请号：DK95937397

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDREN S HOSPITAL AND REGION

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.

公开(公告)号：CA2242335A1

公开(公告)日：1998-05-22

申请号：CA2242335

申请日：1997-11-13

Applicant: PATHOGENESIS CORP

Inventor： VANDEVANTER DONALD R ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K38/00 ,  A61K38/12 ,  A61P11/00 ,  A61P31/04 ,  C07K7/50 ,  C07K7/62 ,  C07K7/60

Abstract: An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation. The figure shows a general structure of a prodrug colimycin (Figure 1A) and a generic formula of a drug colistin and its components substituents (Figure 1B). A formulation and method for preparation of substantially pure biologically active colistin component, a mixture thereof or a pharmaceutically acceptable salt thereof. A method for treatment and prophylaxis of Pseudomonas aeruginosa, Stenotrophomonas maltophilia or other susceptible pulmonary bacterial infections.

公开(公告)号：AU688166B2

公开(公告)日：1998-03-05

申请号：AU3952295

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDRENS HOSP MEDICAL CENTER

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.

公开(公告)号：CA2179305A1

公开(公告)日：1996-05-02

申请号：CA2179305

申请日：1995-10-17

Applicant: PATHOGENESIS CORP ,  CHILDRENS HOSP MEDICAL CENTER

Inventor： SMITH ARNOLD L ,  RAMSEY BONNIE W ,  MONTGOMERY ALAN B

IPC: A61K9/12 ,  A61K9/00 ,  A61K9/72 ,  A61K31/702 ,  A61K31/715 ,  A61P31/04 ,  A61K31/73

Abstract: An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 mu , produced by a jet or ultrasonic nebulizer.